BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bordron A, Bagacean C, Mohr A, Tempescul A, Bendaoud B, Deshayes S, Dalbies F, Buors C, Saad H, Berthou C, Pers JO, Renaudineau Y. Resistance to complement activation, cell membrane hypersialylation and relapses in chronic lymphocytic leukemia patients treated with rituximab and chemotherapy. Oncotarget 2018;9:31590-605. [PMID: 30167081 DOI: 10.18632/oncotarget.25657] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Xie CB, Jane-Wit D, Pober JS. Complement Membrane Attack Complex: New Roles, Mechanisms of Action, and Therapeutic Targets. Am J Pathol 2020;190:1138-50. [PMID: 32194049 DOI: 10.1016/j.ajpath.2020.02.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
2 Interdonato A, Choblet S, Sana M, Valgardsdottir R, Cribioli S, Alzani R, Roth M, Duonor-Cerutti M, Golay J. BL-01, an Fc-bearing, tetravalent CD20 × CD5 bispecific antibody, redirects multiple immune cells to kill tumors in vitro and in vivo. Cytotherapy 2021:S1465-3249(21)00749-0. [PMID: 34538717 DOI: 10.1016/j.jcyt.2021.07.012] [Reference Citation Analysis]
3 Felberg A, Taszner M, Urban A, Majeranowski A, Jaskuła K, Jurkiewicz A, Stasiłojć G, Blom AM, Zaucha JM, Okrój M. Monitoring of the Complement System Status in Patients With B-Cell Malignancies Treated With Rituximab. Front Immunol 2020;11:584509. [PMID: 33329558 DOI: 10.3389/fimmu.2020.584509] [Reference Citation Analysis]
4 Debant M, Burgos M, Hemon P, Buscaglia P, Fali T, Melayah S, Le Goux N, Vandier C, Potier-Cartereau M, Pers JO, Tempescul A, Berthou C, Bagacean C, Mignen O, Renaudineau Y. STIM1 at the plasma membrane as a new target in progressive chronic lymphocytic leukemia. J Immunother Cancer 2019;7:111. [PMID: 31014395 DOI: 10.1186/s40425-019-0591-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
5 Taylor RP, Lindorfer MA. How Do mAbs Make Use of Complement to Kill Cancer Cells? The Role of Ca2. Antibodies (Basel) 2020;9:E45. [PMID: 32899722 DOI: 10.3390/antib9030045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Jiang R, Fichtner ML, Hoehn KB, Pham MC, Stathopoulos P, Nowak RJ, Kleinstein SH, O'Connor KC. Single-cell repertoire tracing identifies rituximab-resistant B cells during myasthenia gravis relapses. JCI Insight 2020;5:136471. [PMID: 32573488 DOI: 10.1172/jci.insight.136471] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
7 Miller ML, Finn OJ. Flow cytometry-based assessment of direct-targeting anti-cancer antibody immune effector functions. Methods Enzymol 2020;632:431-56. [PMID: 32000909 DOI: 10.1016/bs.mie.2019.07.026] [Reference Citation Analysis]
8 Zhong Z, Li H, Zhong H, Zhou T. Clinical efficacy and safety of rituximab in lupus nephritis. Drug Des Devel Ther 2019;13:845-56. [PMID: 30880917 DOI: 10.2147/DDDT.S195113] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Duarte I, Oliveira J, Outerelo C, Godinho I, Pereira M, Fernandes P, Jorge S, Gameiro J. Rituximab in glomerular diseases: a case series and narrative review. J Bras Nefrol 2021:S0101-28002021005081301. [PMID: 34874051 DOI: 10.1590/2175-8239-JBN-2021-0120] [Reference Citation Analysis]
10 Eltahir M, Fletcher E, Dynesius L, Jarblad JL, Lord M, Laurén I, Zekarias M, Yu X, Cragg MS, Hammarström C, Levedahl KH, Höglund M, Ullenhag G, Mattsson M, Mangsbo SM. Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients. Int Immunopharmacol 2021;90:107226. [PMID: 33316742 DOI: 10.1016/j.intimp.2020.107226] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Fishelson Z, Kirschfink M. Complement C5b-9 and Cancer: Mechanisms of Cell Damage, Cancer Counteractions, and Approaches for Intervention. Front Immunol 2019;10:752. [PMID: 31024572 DOI: 10.3389/fimmu.2019.00752] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
12 Dobie C, Skropeta D. Insights into the role of sialylation in cancer progression and metastasis. Br J Cancer 2021;124:76-90. [PMID: 33144696 DOI: 10.1038/s41416-020-01126-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
13 Bagacean C, Tempescul A, Ternant D, Banet A, Douet-Guilbert N, Bordron A, Bendaoud B, Saad H, Zdrenghea M, Berthou C, Paintaud G, Renaudineau Y. 17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia. J Immunother Cancer 2019;7:22. [PMID: 30696487 DOI: 10.1186/s40425-019-0509-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
14 Golay J, Taylor RP. The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs. Antibodies (Basel) 2020;9:E58. [PMID: 33126570 DOI: 10.3390/antib9040058] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]